Navigation Links
Marco LM-990A

ProductsMarco LM-990A
Company Marco Ophthalmic, Inc.
Item Marco LM-990A
Features 
  • Automatic PD
  • Automatic read
  • Automatic prism
  • Three modes: standard, progressive, and contact lens
  • User-friendly icons
  • Automatic R/L recognition
  • Average measuring time of 0.1 second
  • Automatic Abbe
  • Description The LM-990A is the most completely automatic lensemeter ever created. It even measured monocular and binocular PD automatically.
    Info Marco Ophthalmic, Inc.
    Customer Service: (800) 874-5274
    Web site: http://www.marcooph.com/home.html

    Related medicine products :

    1. Marco RT-300
    2. Marco Surgiscope 3
    3. Marco CP-1 Chart Projector
    4. Marco LM-970
    5. Marco Spectrum 2
    6. National Eyewear Collection by Marcolin
    7. Marcolin Eyewear Collection
    8. LM-990A
    ... instruments have been designed to provide ... tool for situations requiring precise hemostasis. ... 25 gauge intraocular, bipolar, diathermy instruments. ... target tissues for fine-tip hemostasis or ...
    ... first steps any hospital or health system ... powerful, most effective tools available for physicians ... clinician documentation and electronic medical record (EMR) ... this goal. In fact, its the most ...
    ... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
    ... ChartingPlus proves itself to over 2,000 medical ... with the user in mind, ChartingPlus relies ... and dynamic features to improve documentation quality ... Our medical content is specific ...
    Medicine Products:
    (Date:9/22/2014)... 2014 Don Allred Insurance is pleased to ... Burlington, NC. The satellite office, located in the Holly Hill ... 15, 2014, and offer all of the same professional services ... Allred Insurance spokesperson Scott Allred cites an expanding client base ... two of the major factors driving the decision to open ...
    (Date:9/22/2014)... 22, 2014 Ethane Web Technologies, an ... to have announced affordable website redesign. The website redesign ... which are unsatisfied with their present websites and want ... to pay a big amount for this job. ... advanced tool, techniques, and experienced manpower so that it ...
    (Date:9/22/2014)... Colorado's grand experiment with legal recreational marijuana for adults ... revenue for the state. , According to the ... was sold in Colorado dispensaries during the first five ... , But the success of these retail shops has ... the thousands of consumers now seeking out cannabis dispensaries ...
    (Date:9/22/2014)... Available research evidence supports the use of deep ... who don,t respond to other treatments, concludes a review ... , official journal of the Congress of Neurological ... Lippincott Williams & Wilkins , a part of ... specific bilateral DBS techniques are recommended for treatment of ...
    (Date:9/22/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... GLOBAL MARKETS, the global market for autoimmune disease ... billion by 2019, with a five-year compound annual ... holds the highest market potential due to an ... western lifestyles. , In recent decades, autoimmune ...
    Breaking Medicine News(10 mins):Health News:Allred Insurance to Open New Burlington Branch Office 2Health News:Ethane Web Technologies Announces Affordable Website Redesign Service 2Health News:Colorado Cannabis Dispensary Creates a Unique In-Store Sales System, That Leaves the Old-School Retail Approach in the Dust 2Health News:Colorado Cannabis Dispensary Creates a Unique In-Store Sales System, That Leaves the Old-School Retail Approach in the Dust 3Health News:Evidence supports deep brain stimulation for obsessive-compulsive disorder 2Health News:Evidence supports deep brain stimulation for obsessive-compulsive disorder 3Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 2Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 3
    ... By Jenifer Goodwin HealthDay Reporter , TUESDAY, ... receive fewer blood transfusions do just as well as those ... of blood transfusions varies widely among U.S. hospitals. The ... Journal of the American Medical Association . In ...
    ... murine leukemia virusrelated virus (XMRV) has been the subject ... conflicting reports have created an unclear picture of XMRV,s ... in the November 15 issue of The Journal ... supports a possible link between XMRV and prostate cancer ...
    ... molecule they designed can block activation of a gene in ... those cancer cells to survive chemotherapy. Without the ... to be protected from the toxic effects of chemotherapy drugs. ... protecting the cells, the research suggests. As a result, more ...
    ... By Amanda Gardner HealthDay Reporter , TUESDAY, Oct. ... cancer patients treated with bisphosphonate drugs such as Aredia or ... be at higher risk for the irregular heartbeat known as ... atrial fibrillation, the upper chambers of the heart beat chaotically, ...
    ... results of a large Phase-III clinical trial have shown ... with a hard-to-treat group of rare cancers that affect ... the European Society for Medical Oncology (ESMO), Dr Marianne ... everolimus improved progression-free survival by 5.1 months in patients ...
    ... of breast cancer can lead some women to wonder if ... of more than 85,000 postmenopausal women, published in BioMed Central,s ... regular physical activity, maintaining a healthy weight, and drinking less ... a family history of the disease. The University of ...
    Cached Medicine News:Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 2Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 3Health News:New studies examine links between XMRV and human disease 2Health News:New studies examine links between XMRV and human disease 3Health News:Blocking an oncogene in liver cancer could be potential therapy option 2Health News:Blocking an oncogene in liver cancer could be potential therapy option 3Health News:Cancer-Fighting Bone Drugs Might Raise Stroke Risk 2Health News:Cancer-Fighting Bone Drugs Might Raise Stroke Risk 3Health News:Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors 2
    (Date:9/22/2014)... DALLAS , September 22, 2014 ... report "Cell Line Development Market by Product (Equipment, Media ... (Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, ... to 2019", published by MarketsandMarkets, analyzes and studies ... Browse 114 market data tables ...
    (Date:9/22/2014)... 2014 CytRx Corporation (Nasdaq: CYTR ... oncology, today announced that study designs and progress from ... a pivotal global Phase 3 clinical trial in relapsed/refractory ... clinical trial in small cell lung cancer, will be ... 2014 Congress being held September 26-30, in ...
    (Date:9/19/2014)... Sept. 19, 2014 Harwood Feffer LLP ( ... of directors of PDL BioPharma, Inc. ("PDL" or the ... board has breached its fiduciary duties to shareholders or ... 16, 2014, the Company disclosed: "On September 11, 2014, ... firm, Ernst & Young LLP ("EY"), that it was ...
    Breaking Medicine Technology:Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2